Edwards Lifesciences Corp
Change company Symbol lookup
Select an option...
EW Edwards Lifesciences Corp
COP ConocoPhillips
FBP First Bancorp
PTCT PTC Therapeutics Inc
ROKU Roku Inc
WORK Slack Technologies Inc
ARKW ARK Next Generation Internet ETF
SPOT Spotify Technology SA
GBTC Grayscale Bitcoin Trust (BTC)
ARKK ARK Innovation ETF
Go

Health Care : Health Care Equipment & Supplies | Large Cap Growth
Company profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.

Closing Price
$87.87
Day's Change
0.38 (0.43%)
Bid
--
Ask
--
B/A Size
--
Day's High
88.15
Day's Low
86.84
Volume
(Heavy Day)
Volume:
3,128,902

10-day average volume:
2,258,643
3,128,902

SHAREHOLDER ALERT: LOOP LVS ICPT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

2:05 pm ET November 23, 2020 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / November 23, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Loop Industries, Inc. (NASDAQ:LOOP)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/loop-industries-inc-loss-submission-form?prid=11147&wire=1Lead Plaintiff Deadline: December 14, 2020Class Period: September 24, 2018 - October 12, 2020

Allegations against LOOP include that: (1) Loop scientists were encouraged to misrepresent the results of Loop's purportedly proprietary process; (2) Loop did not have the technology to break PET down to its base chemicals at a recovery rate of 100%; (3) as a result, the Company was unlikely to realize the purported benefits of Loop's announced partnerships with Indorama Ventures Public Company Limited and thyssenkrupp Industrial Solutions; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Las Vegas Sands Corp. (NYSE:LVS)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/las-vegas-sands-corp-loss-submission-form?prid=11147&wire=1Lead Plaintiff Deadline: December 21, 2020Class Period: February 27, 2016 - September 15, 2020

Allegations against LVS include that: (i) weaknesses existed in Marina Bay Sands' casino control measures pertaining to fund transfers; (ii) the Marina Bay Sands' casino was consequently prone to illicit fund transfers that implicated, among other issues, the transfer of customer funds to unauthorized persons and potential breaches in the Company's anti-money laundering procedures; (iii) the foregoing foreseeably increased the risk of litigation against the Company, as well as investigation and increased oversight by regulatory authorities; (iv) Las Vegas Sands had inadequate disclosure controls and procedures; (v) consequently, all the foregoing issues were untimely disclosed; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/intercept-pharmaceuticals-inc-loss-submission-form?prid=11147&wire=1Lead Plaintiff Deadline: January 4, 2021Class Period: September 28, 2019 - October 7, 2020

Allegations against ICPT include that: (i) Defendants downplayed the true scope and severity of safety concerns associated with the use of Ocaliva (obeticholic acid ("OCA")), Intercept's lead product candidate, in treating primary biliary cholangitis; (ii) the foregoing increased the likelihood of a U.S. Food and Drug Administration ("FDA") investigation into Ocaliva's development, thereby jeopardizing Ocaliva's continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA's efficacy in treating nonalcoholic steatohepatitis ("NASH") were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company's New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.39 East BroadwaySuite 304New York, NY 10002Tel. 212.425.1140Fax. 866.699.3880E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

View source version on accesswire.com: https://www.accesswire.com/618023/SHAREHOLDER-ALERT-LOOP-LVS-ICPT-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.